147 results on '"Batalini, Felipe"'
Search Results
2. Reciprocal antagonism of PIN1-APC/CCDH1 governs mitotic protein stability and cell cycle entry
3. Safety and Serum Estradiol Levels in Hormonal Treatments for Vulvovaginal Atrophy in Breast Cancer Survivors: A Systematic Review and Meta-Analysis
4. Framework for Exposing Vulnerabilities of Clinical Large Language Model: A Case Study in Breast Cancer
5. Artificial intelligence for triaging of breast cancer screening mammograms and workload reduction: A meta-analysis of a deep learning software.
6. Cardiac Tumors: Review.
7. Reciprocal antagonism of PIN1-APC/CCDH1 governs mitotic protein stability and cell cycle entry.
8. Artificial intelligence for triaging of breast cancer screening mammograms and workload reduction: A meta-analysis of a deep learning software
9. Metastatic ER+ Breast Cancer: Mechanisms of Resistance and Future Therapeutic Approaches
10. Homologous Recombination Deficiency Landscape of Breast Cancers and Real-World Effectiveness of Poly ADP-Ribose Polymerase Inhibitors in Patients With Somatic BRCA1/2, Germline PALB2, or Homologous Recombination Deficiency Signature
11. High-Dose Melphalan and Stem Cell Transplantation in Patients on Dialysis Due to Immunoglobulin Light-Chain Amyloidosis and Monoclonal Immunoglobulin Deposition Disease
12. Targeting of microRNA-22 Suppresses Tumor Spread in a Mouse Model of Triple-Negative Breast Cancer
13. Supplementary Figure from Mutational Signature 3 Detected from Clinical Panel Sequencing is Associated with Responses to Olaparib in Breast and Ovarian Cancers
14. Supplementary Table from Mutational Signature 3 Detected from Clinical Panel Sequencing is Associated with Responses to Olaparib in Breast and Ovarian Cancers
15. Homologous Recombination Deficiency Landscape of Breast Cancers and Real-World Effectiveness of Poly ADP-Ribose Polymerase Inhibitors in Patients With Somatic BRCA1 / 2 , Germline PALB2 , or Homologous Recombination Deficiency Signature.
16. Supplementary Figure from Phase 1b Clinical Trial with Alpelisib plus Olaparib for Patients with Advanced Triple-Negative Breast Cancer
17. Supplementary Table from Phase 1b Clinical Trial with Alpelisib plus Olaparib for Patients with Advanced Triple-Negative Breast Cancer
18. Therapy-related Myeloid Neoplasms Following PARP Inhibitors—Letter
19. Abstract P3-04-06: Artificial intelligence-based triaging of breast cancer screening mammograms and radiologist workload reduction: a systematic review and meta-analysis
20. Abstract P4-01-08: Efficacy of PARP Inhibitors in Patients With BRCA1/2-related Breast Cancer with Prior Platinum Exposure: A Systematic Review and Meta-Analysis
21. Abstract P4-01-22: Clinical outcomes of metastatic breast cancer patients treated with poly (adenosine diphosphate-ribose) polymerase inhibitors (PARPi): the Mayo Clinic experience
22. Abstract P5-12-03: Intratumor heterogeneity and intrinsic immune activation are associated with response to chemotherapy in BRCA-related breast cancers
23. Survival of patients with colorectal cancer (CRC) with low expression of homologous recombination proficient (HRP) genes.
24. Comparison of PARPi efficacy according to homologous recombination deficiency biomarkers in patients with ovarian cancer: a systematic review and meta-analysis
25. Li-Fraumeni syndrome: not a straightforward diagnosis anymore—the interpretation of pathogenic variants of low allele frequency and the differences between germline PVs, mosaicism, and clonal hematopoiesis
26. CEM and MR Radiomics-based Biomarkers to Predict Immunohistochemistry Breast Cancer Subtypes: A comparative study
27. PARP-inhibition reprograms macrophages toward an anti-tumor phenotype
28. Interventions that reduce disparities in management along the cancer care continuum: a scoping review protocol
29. PARP Inhibitors for Breast Cancer: Germline BRCA1/2 and Beyond
30. Mutational Signature 3 Detected from Clinical Panel Sequencing is Associated with Responses to Olaparib in Breast and Ovarian Cancers
31. Artificial intelligence for prediction of treatment outcomes in breast cancer: Systematic review of design, reporting standards, and bias
32. Evaluation of homologous recombination deficiency biomarkers in patients with ovarian cancer treated with PARP inhibitors.
33. An overview of artificial intelligence in oncology
34. Response in BRCA1 mutation carrier with metastatic pancreatic adenocarcinoma treated with FOLFIRINOX
35. Phase 1b Clinical Trial with Alpelisib plus Olaparib for Patients with Advanced Triple-Negative Breast Cancer
36. Abstract 156: Mutational signature 3 predicts responses to olaparib plus buparlisib in triple-negative breast cancer and high-grade serous ovarian cancer
37. Analysis of real-world (RW) data for metastatic breast cancer (mBC) patients (pts) with somatic BRCA1/2 (sBRCA) or other homologous recombination (HR)-pathway gene mutations (muts) treated with PARP inhibitors (PARPi).
38. Germline genetic testing in breast cancer: Rationale for the testing of all women diagnosed by the age of 60 years and for risk‐based testing of those older than 60 years
39. Challenges in Interpreting TP53 Pathogenic Variants With a Low Minor Allele Frequency in Germline Genetic Testing: A Case Report of a Patient With Mosaic Li-Fraumeni Syndrome
40. Response of Brain Metastases From PIK3CA-Mutant Breast Cancer to Alpelisib
41. Double-hit monomorphic B-cell lymphoma after liver transplantation
42. Overcoming barriers to resident scholarly productivity and research at a large academic institution
43. Haemodialysis-associated thrombocytopenia: interactions among the immune system, membranes and sterilisation methods
44. Temozolomide-induced aplastic anaemia and incidental low-grade B-cell non-Hodgkin lymphoma in a geriatric patient with glioblastoma multiforme
45. Severe pulmonary toxicity from immune checkpoint inhibitor treated successfully with intravenous immunoglobulin: Case report and review of the literature
46. Acute promyelocytic leukaemia presenting as necrotising fasciitis of the perineum (Fournier gangrene)
47. Germline genetic testing in breast cancer: Rationale for the testing of all women diagnosed by the age of 60 years and for risk‐based testing of those older than 60 years.
48. Cancer complaints: The profile of patients from the emergency department of a Brazilian oncology teaching hospital
49. Off-Pump Triple Coronary Artery Bypass Grafting in a Patient with Situs Inversus Totalis: Case Presentation and a Brief Review of the Brazilian and the International Experiences
50. Improvement of Dream Enactment Behavior Associated With Levetiracetam Treatment in Dementia With Lewy Bodies
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.